Navigation Links
Cellular Biomedicine Group Announces New Product Approved for Market in China and New Exclusive License
Date:10/30/2013

PALO ALTO, Calif., Oct. 30, 2013 /PRNewswire/ -- Today Cellular Biomedicine Group (OTCQB:CBMG) announced that their A-Stromal™ adipose stromal cell purification kit is ready to launch on the market in China. In addition, they have signed an exclusive China and Hong Long license for ProCeller computer controlled processing system to extract stem cells from adipose tissue. These two products, when used together, allow for safe and contaminant-free isolation of one million Vascular Stromal Cells per 1 mL of adipose tissue in as little as sixty minutes. The potential clients for both products are cosmetic clinics, research institutions, sports medicine departments and veterinarian clinics.

About A-Stromal™
The A-Stromal™ kit was developed completely in-house by Cellular Biomedicine Group, Inc. and is covered by two China patents. The China Food and Drug Administration (CFDA) approved this kit as a medical device and it is the first certified product of its kind in China. It contains all critical reagents and material to purify Vascular Stromal Cells (VSC) or Stromal Vascular Fraction (SVF) from adipose (fat) tissue and includes detailed instructions for use and hands-on training.

Dr. William Cao, CEO of Cellular Biomedicine Group, Inc., explained, "The proprietary protocols of the A-Stromal™ kit provide a high concentration of VSC, averaging one million VSC cells per 1 mL of adipose tissue, with greater than 90% cell viability. This allows the doctor to extract a very small amount of adipose tissue from the patient in order to isolate enough VSC required for a therapeutic or cosmetic procedure."

The A-Stromal™ kits will be manufactured in Cellular Biomedicine Group's cGMP-certified facility in Wuxi, China, which has been approved by the CFDA as a manufacturing facility for Medical Devices and is accredited ISO (International Standards Organization) 9001:2008 certification by internationally recognized quality management system SGS.

About ProCeller
Cellular Biomedicine Group HK, Ltd. (a subsidiary of Cellular Biomedicine Group, Inc.) has signed an exclusive license for the China and Hong Kong market with Dr. Hsu-Wei Fang, whose team holds the China patent and Taiwan patent for ProCeller, which is CE-marked. Dr. Fang is a Professor of the Department of Chemical Engineering and Biotechnology of National Taipei University of Technology (Taipei Tech) and brought ProCeller to the Taiwan market over two years ago.

ProCeller is an integrated, all-in-one computerized platform that offers a miniature cleanroom environment to isolate cells. The single piece of equipment is composed of a temperature controlled orbital shaker, integrated vacuum system, integrated centrifuge and HEPA filtered, self-sterilizing environment. It is a user-friendly interface with step-by-step procedures displayed on an LED screen.

"The advantage of the ProCeller equipment," stated Dr. Fang, "is that normally a hospital or clinic would have to dedicate a significant amount of space within the clinic and purchase several pieces of costly equipment and raw materials in order to build their own cleanroom facility to process cells. The ProCeller machine is one integrated piece of equipment that takes up a relatively small amount of space and requires minimal training."

ProCeller has been designed to meet the demands of many clinical and research applications, including isolation of VSC and SVF, purifying fat for lipotransfer in cosmetic surgery, isolating peripheral blood monocytes for immunological study, and separating platelet-rich plasma (PRP) for regenerative medicine use.

Dr. Cao commented, "We are proud to present ProCeller and A-Stromal™ kit as the first integrated system for fat cell processing to the Greater China market."

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit: www.cellbiomedgroup.com 

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contact:
Sarah Kelly 
Director of Corporate Communications, CBMG
+1 650 566 5064
sarah.kelly@cellbiomedgroup.com


'/>"/>
SOURCE Cellular Biomedicine Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
2. Decellularized mouse heart beats again after regenerating with human heart precursor cells
3. Cellular Dynamics International Announces Launch of Initial Public Offering
4. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
5. Cellular Therapy and Cord Blood 2013 Market Report
6. Cellular Biomedicine Group Announces Appointment of Corporate Controller
7. Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents
8. Cellular Dynamics International Files Registration Statement for Proposed Initial Public Offering
9. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
10. Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors
11. Top Genetic and Cellular Researchers Honored at ASGCT 16th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):